Response to review.

Company editor-in-chief:

I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Gastrointestinal Oncology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office’s comments and the Criteria for Manuscript Revision by Authors. Before final acceptance, the author(s) must add a table/figure to the manuscript.

Authors’ response: Thank you for the positive comments. Following the editor’s comment, a table for a list of the clinical trial was added.

Reviewer #1:

Scientific Quality: Grade B (Very good)
Language Quality: Grade A (Priority publishing)
Conclusion: Accept (General priority)

Specific Comments to Authors: Within this manuscript authors reviewed the significance of PARP-1 inhibition in BRCAness pancreatic cancer. In recent years, PARP1 inhibitors have been demonstrated to provide a significant benefit among patients with breast/ovarian cancer and germline BRCA1/2 mutation. The successful results of clinical trials for PARP inhibitors among subtypes offer new ideas for the treatment of pancreatic cancer. The Pancreatic Cancer Olaparib Ongoing trial has demonstrated that the median progression-free survival was observably longer in the olaparib group than in the placebo group. Therefore, the use of PARP inhibitors in pancreatic cancer has broad prospects and may bring hope to this challenging disease. Both PARP1 and BRCAs function in DNA damage repair, so inhibition of PARP1 led to synthetic lethality of BRCAness cancer cells. The molecular mechanisms and clinical applications of PARP inhibitors in cancers (including pancreatic cancer) have been
discussed in many papers, e.g., Mol Cancer, 2020, 19(1): 49., Science, 2017, 355(6330): 1152-1158. I have no doubt about the topic of this manuscript.

**Authors’ response:** Thank you for the positive comments.